Results 101 to 110 of about 8,252,790 (324)
Conserved binding mode but diverse interfaces of MreC‐PBP2 interactions
The crystal structure of abMreC reveals a conserved two β‐barrel architecture and provides structural insights into its role within the bacterial elongasome. The abMreC–abPBP2 complex model identifies the molecular basis of MreC‐mediated PBP2 recognition, contributing to the regulation of peptidoglycan synthesis.
Hyunseok Jang +4 more
wiley +1 more source
Fatal Flaws in the Food and Drug Administration\u27s Drug-Approval Formula [PDF]
The mission of the Food and Drug Administration (FDA) is to protect and serve the public by regulating drugs and medical devices. The scope of the FDA\u27s regulatory power is broad; the agency controls the clinical research, approval, and subsequent ...
Bean, Melissa Marie
core +1 more source
Kenneth Lundstrom PanTherapeutics, Lutry, Switzerland Abstract: Oncolytic viruses have demonstrated selective replication and killing of tumor cells.
Lundstrom K
doaj
Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta +3 more
wiley +1 more source
Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules? [PDF]
Much has been written about the seemingly less formal, more agile biotechnology industry and its extensive interactions with academia and startups, as well as its distinct scientific, manufacturing and regulatory profile.
Mark Trusheim +2 more
core
Physicians’ Trust in the FDA’s Use of Product-Specific Pathways for Generic Drug Approval
Background Generic drugs are cost-effective versions of brand-name drugs approved by the Food and Drug Administration (FDA) following proof of pharmaceutical equivalence and bioequivalence.
A. Kesselheim +8 more
semanticscholar +1 more source
Structure‐forward targeting of claudins with synthetic binders
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley +1 more source
Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang +2 more
wiley +1 more source
Background: Clinical trials are conducted with a set of ethical standards, patient safety measures, and scientific scrutiny. Clinical Data Management Systems have evolved over time, shaped by historical milestones, technological advancement, and ...
Thrupthi D L +4 more
doaj +1 more source

